Immuno Cancer Biotherapeutics, Inc. — SEC Form D Filing

Immuno Cancer Biotherapeutics, Inc. filed an SEC Form D on October 15, 2026, reporting $75K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 15, 2026
Amount reported
$75K
Round stage
Pre-Seed
Industry
Biotechnology
Website
https://www.icbiothera.com/

What the company does

Securities: SAFE (Simple Agreement for Future Equity). Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Cancer cells within tumors are not uniform and exhibit heterogeneity, which allows sub-populations of cells to thrive and expand when treatments target only a single antigen. Many existing cancer treatments rely on a single killing mechanism, leading to drug resistance.

Solution

Immuno Cancer Biotherapeutics is developing hyperimmune human polyclonal antibodies (hPAb) designed to broadly target numerous antigens and epitopes on diverse populations of cancer cells. These hPAbs employ multiple modes of killing to overcome cancer heterogeneity and resistance.

Why now

Advances in genetic engineering and antibody production technologies, spearheaded by their co-founder, enable the development and application of complex human polyclonal antibody platforms for cancer treatment.

Verdict

This cleared because the underlying biological mechanism offered a plausible workaround for known oncology resistance pathways, not because of demonstrated clinical efficacy or a clear path to market. Investors were implicitly betting on the founders' technical expertise to validate the core science and de-risk early-stage preclinical development. The limited upside stemmed from the long, capital-intensive development timeline inherent in novel biologic platforms, requiring subsequent significant raises before any commercial validation.

Source: SEC EDGAR Form D filing